Cartesian Therapeutics, Inc. — Director's Dealing 2022

Dec 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-12-05

Reporting Person: Brunn Carsten (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-05	Common Stock	S	4522	$1.33	Disposed	544283	Direct

Footnotes

F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.